Anifrolumab (Saphnelo) listed in NS

March 6, 2024 – Lupus Canada is pleased to share that Saphnelo has been listed in Nova Scotia effective March 1, 2024.

The public notice and listing criteria will appear on the Nova Scotia Pharmacare Programs website when the March Bulletin is posted.

Lupus Blog Articles:

Nuvaxovid in Canada: How to Access the COVID-19 Vaccine

Read

Lupus Fatigue and Exercise: Practical Movement Strategies

Read

Invisible Disability and Lupus: When Disability Isn’t Visible | Lupus Canada

Read